JP2019504070A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504070A5
JP2019504070A5 JP2018536455A JP2018536455A JP2019504070A5 JP 2019504070 A5 JP2019504070 A5 JP 2019504070A5 JP 2018536455 A JP2018536455 A JP 2018536455A JP 2018536455 A JP2018536455 A JP 2018536455A JP 2019504070 A5 JP2019504070 A5 JP 2019504070A5
Authority
JP
Japan
Prior art keywords
formulation
injectable
nacl
compound
examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018536455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504070A (ja
Filing date
Publication date
Priority claimed from FR1670004A external-priority patent/FR3046793B1/fr
Application filed filed Critical
Publication of JP2019504070A publication Critical patent/JP2019504070A/ja
Publication of JP2019504070A5 publication Critical patent/JP2019504070A5/ja
Pending legal-status Critical Current

Links

JP2018536455A 2016-01-14 2017-01-13 新規ホスフィナン及びアザホスフィナン誘導体、それらを調製するための方法、並びにそれらを含有する医薬組成物 Pending JP2019504070A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR16/70004 2016-01-14
FR1670004A FR3046793B1 (fr) 2016-01-14 2016-01-14 Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2017/050075 WO2017121969A1 (fr) 2016-01-14 2017-01-13 Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
JP2019504070A JP2019504070A (ja) 2019-02-14
JP2019504070A5 true JP2019504070A5 (enExample) 2019-11-28

Family

ID=55752640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536455A Pending JP2019504070A (ja) 2016-01-14 2017-01-13 新規ホスフィナン及びアザホスフィナン誘導体、それらを調製するための方法、並びにそれらを含有する医薬組成物

Country Status (47)

Country Link
US (2) US10138260B2 (enExample)
EP (1) EP3271368B1 (enExample)
JP (1) JP2019504070A (enExample)
KR (1) KR20180101522A (enExample)
CN (1) CN108495857A (enExample)
AR (1) AR107433A1 (enExample)
AU (1) AU2017207003B2 (enExample)
BR (1) BR112018014020A2 (enExample)
CA (1) CA3011184C (enExample)
CL (1) CL2018001862A1 (enExample)
CO (1) CO2018007271A2 (enExample)
CU (1) CU20180072A7 (enExample)
CY (1) CY1121154T1 (enExample)
DK (1) DK3271368T3 (enExample)
DO (1) DOP2018000165A (enExample)
EA (1) EA035072B1 (enExample)
EC (1) ECSP18051972A (enExample)
ES (1) ES2709376T3 (enExample)
FR (1) FR3046793B1 (enExample)
GE (1) GEP20207092B (enExample)
HK (1) HK1244283B (enExample)
HR (1) HRP20190193T1 (enExample)
HU (1) HUE042924T2 (enExample)
IL (1) IL260425B (enExample)
JO (1) JO3660B1 (enExample)
LT (1) LT3271368T (enExample)
MA (1) MA41798B1 (enExample)
MD (1) MD3271368T2 (enExample)
ME (1) ME03305B (enExample)
MX (1) MX367319B (enExample)
NI (1) NI201800073A (enExample)
PE (1) PE20181503A1 (enExample)
PH (1) PH12018501373A1 (enExample)
PL (1) PL3271368T3 (enExample)
PT (1) PT3271368T (enExample)
RS (1) RS58338B1 (enExample)
RU (1) RU2729641C2 (enExample)
SG (1) SG11201805757WA (enExample)
SI (1) SI3271368T1 (enExample)
SV (1) SV2018005721A (enExample)
TN (1) TN2018000226A1 (enExample)
TR (1) TR201820430T4 (enExample)
TW (1) TWI625334B (enExample)
UA (1) UA121275C2 (enExample)
UY (1) UY37072A (enExample)
WO (1) WO2017121969A1 (enExample)
ZA (1) ZA201804391B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001425A (es) * 2000-08-17 2003-06-06 Pfizer Compuestos farmaceuticos.
SE0103272D0 (sv) * 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
AU2002249275A1 (en) * 2002-03-08 2003-09-22 Warner-Lambert Company Llc Oxo azabicyclic compounds
US7420000B2 (en) * 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
US20050143349A1 (en) * 2003-12-17 2005-06-30 Quatrx Pharmaceuticals Co. Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels
EP1874322A1 (en) * 2005-04-18 2008-01-09 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
US8367706B2 (en) * 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
FR2920773B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112012005438A2 (pt) * 2009-09-09 2018-03-20 Gilead Sciences Inc inibidores de vírus flaviviridae
MX2015000830A (es) * 2012-07-18 2015-10-26 Sunshine Lake Pharma Co Ltd Derivados heterociclicos nitrogenosos y su aplicacion en farmacos.
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Similar Documents

Publication Publication Date Title
JP2015078230A5 (enExample)
CL2019003669A1 (es) Inhibidores de quinasa alk2 que contienen imidazol.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX385984B (es) Inhibidores de isoindolinona de la interacción mdm2-p53 que tienen actividad antineoplásica.
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
EA201892734A1 (ru) ПРОИЗВОДНЫЕ АЗАБЕНЗИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ pI3K BETA
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
MX379900B (es) Inhibidores de isoindolinona de la interaccion mdm2-p53 que tienen actividad antineoplasica.
MX373040B (es) Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservador.
MX374628B (es) Formulacion que comprende un agente hipolipidemico.
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
EA201890532A1 (ru) Новые аннелированные бензамиды
MX383577B (es) Derivados sustituidos de guanidina.
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
PH12015501945B1 (en) Formulations of organic compounds
MX2017015812A (es) Formulaciones farmaceuticas inyectables de lefamulina.
MY182634A (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
JOP20170197A1 (ar) الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول
JP2019504070A5 (enExample)
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
HRP20201598T1 (hr) Pripravci
MX2019006939A (es) Preparacion liquida parenteral que comprende compuesto de carbamato.
EA201890477A1 (ru) Инкапсулированная композиция финголимода